Literature DB >> 7678795

Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues.

W L Kuo1, A G Montag, M R Rosner.   

Abstract

Insulin-degrading enzyme (IDE), a cytosolic metalloendoprotease, can degrade insulin, insulin-like growth factor-II, insulin-like growth factor-I, and transforming growth factor-alpha. While IDE has been implicated in the cellular degradation of insulin, other physiological functions of this enzyme are not known. To assess the possible role of IDE in cellular growth and development, we determined the tissue and developmental distribution of the enzyme. Rat IDE cDNA fragments and antibodies directed against human IDE were used to probe IDE transcripts and proteins in rat tissues. The results demonstrate that IDE transcripts are ubiquitous in rat tissues. The level of rIDE transcripts is high in adult rat testis, tongue, and brain; moderate in kidney, prostate, heart, muscle, liver, intestine, and skin; and low in spleen, lung, thymus, and uterus. The sizes of the major transcripts of rIDE are 3.4 and 6.3 kilobases in all tissues analyzed, except testis. Surprisingly, the highest level of rIDE mRNA in the adult rat was in the testis, and the major transcripts of rIDE in this tissue were shifted in size to 3.8 and 6.7 kilobases. Immunocytochemical analysis localized the rIDE mainly in the epithelium of prostate gland and kidney, and the cytosol of liver hepatocytes. During rat development from 6-7 days of age to adulthood, rIDE mRNA levels increased in brain, testis, and tongue; decreased in muscle and skin; and did not significantly change in other tissues examined. These studies reveal regulation of IDE or IDE-related genes in rat tissues and during rat development, suggesting that this enzyme may have multiple functions relating to cellular growth and development.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678795     DOI: 10.1210/endo.132.2.7678795

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  33 in total

1.  Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization.

Authors:  V Chesneau; K Vekrellis; M R Rosner; D J Selkoe
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

Authors:  A Pérez; L Morelli; J C Cresto; E M Castaño
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

3.  Insulin-degrading enzyme in a human colon adenocarcinoma cell line (Caco-2).

Authors:  J P Bai; M J Hsu; W T Shier
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

4.  In vitro degradation of insulin-like peptide 3 by insulin-degrading enzyme.

Authors:  Wei-Jie Zhang; Xiao Luo; Zhan-Yun Guo
Journal:  Protein J       Date:  2010-02       Impact factor: 2.371

5.  17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention.

Authors:  Liqin Zhao; Jia Yao; Zisu Mao; Shuhua Chen; Yan Wang; Roberta Diaz Brinton
Journal:  Neurobiol Aging       Date:  2010-01-06       Impact factor: 4.673

6.  Transcriptional regulation of insulin-degrading enzyme modulates mitochondrial amyloid β (Aβ) peptide catabolism and functionality.

Authors:  María C Leal; Natalia Magnani; Sergio Villordo; Cristina Marino Buslje; Pablo Evelson; Eduardo M Castaño; Laura Morelli
Journal:  J Biol Chem       Date:  2013-03-22       Impact factor: 5.157

7.  Immunohistochemical evidence of ubiquitous distribution of the metalloendoprotease insulin-degrading enzyme (IDE; insulysin) in human non-malignant tissues and tumor cell lines.

Authors:  Gregor Weirich; Karin Mengele; Christina Yfanti; Apostolos Gkazepis; Daniela Hellmann; Anita Welk; Cecylia Giersig; Wen-Liang Kuo; Marsha Rich Rosner; Wei-Jen Tang; Manfred Schmitt
Journal:  Biol Chem       Date:  2008-11       Impact factor: 3.915

8.  Glucose inhibits the insulin-induced activation of the insulin-degrading enzyme in HepG2 cells.

Authors:  O Pivovarova; O Gögebakan; A F H Pfeiffer; N Rudovich
Journal:  Diabetologia       Date:  2009-04-25       Impact factor: 10.122

Review 9.  The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses.

Authors:  Laura Morelli; Ramiro Llovera; Sandra Ibendahl; Eduardo M Castaño
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

Review 10.  Mechanisms of Abeta clearance and catabolism.

Authors:  Suzanne Y Guénette
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.